Pain – Opioids

  • Nucynta 2015 report

    Nucynta 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 31 Pages The 5 Key Questions Addressed by this...

  • Opana 2015 report

    Opana 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 29 Pages The 5 Key Questions Addressed by this...

  • OxyContin 2015 report

    OxyContin 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 29 Pages The 5 Key Questions Addressed by this...

  • Subsys 2015 report

    Subsys 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 31 Pages The 5 Key Questions Addressed by this...

  • Xartemis XR 2015 report

    Xartemis XR 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 35 Pages The 5 Key Questions Addressed by...

  • Zohydro ER 2015 report

    Zohydro ER 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 29 Pages The 5 Key Questions Addressed by...

  • Abstral 2014 report

    Abstral 2014 U.S. PROMOTIONAL AUDIT REPORT Published July 2015 • 33 Pages The 5 Key Questions Addressed by this...

  • Butrans 2014 report

    Butrans 2014 U.S. PROMOTIONAL AUDIT REPORT Published July 2015 • 29 Pages The 5 Key Questions Addressed by this...

  • Exalgo 2014 report

    Exalgo 2014 U.S. PROMOTIONAL AUDIT REPORT Published July 2015 • 31 Pages The 5 Key Questions Addressed by this...

  • Fentora 2014 report

    Fentora 2014 U.S. PROMOTIONAL AUDIT REPORT Published July 2015 • 32 Pages The 5 Key Questions Addressed by this...

  • Lazanda 2014 report

    Lazanda 2014 U.S. PROMOTIONAL AUDIT REPORT Published July 2015 • 33 Pages The 5 Key Questions Addressed by this...

  • Nucynta 2014 report

    Nucynta 2014 U.S. PROMOTIONAL AUDIT REPORT Published July 2015 • 28 Pages The 5 Key Questions Addressed by this...